Peter Lawson News
-
Tory Galloway thought her negative result on a widely-used test sold by Myriad Genetics Inc. cleared her DNA as a cause for her fallopian tube cancer.
-
Illumina Inc. gained the most in almost a year after Swiss newspaper L’Agefi said Roche Holding AG may have agreed to buy the U.S. maker of DNA sequencing equipment at a price 48 percent higher than its original unsuccessful bid.
-
PerkinElmer Inc. made a bet-the-farm offer to take over Beckman Coulter Inc. and had the highest bid in the final hours of this month’s auction for the medical- equipment maker, according to regulatory filings and people with knowledge of the matter.
-
Cleveland, which has poured almost $1 billion into such projects as three sports stadiums and the Rock & Roll Hall of Fame, is on the verge of spending $465 million in an effort to remake itself as the epicenter for the sale of medical equipment and supplies.
-
Gen-Probe Inc. , a maker of tests for AIDS and the West Nile virus, hired Morgan Stanley to seek a buyer for the company, according to three people with knowledge of the sale. The shares rose the most in almost seven years.
-
Gen-Probe Inc. , the tester of sexually transmitted diseases that jumped 18 percent on speculation it will be sold, may still be worth $1.3 billion more in a takeover by Novartis AG or Life Technologies Corp.
-
Jay Flatley, the Illumina Inc. chief executive who lifted revenue from $1 million to $1 billion over 12 years, persuaded investors to support his rejection of Roche Holding AG’s takeover bid.
-
In the busiest year for medical products takeovers, potential acquirers can now scoop up Becton, Dickinson & Co. at the cheapest valuation since 1993.
-
Gen-Probe Inc. fell the most in six years in Nasdaq trading after the Wall Street Journal reported Novartis AG may not bid for the medical-test maker, leaving it with no suitors.
-
Thermo Fisher Scientific Inc. , the largest maker of laboratory instruments, rose to a record high in New York trading after agreeing to buy Sweden’s Phadia AB to expand in testing for allergies and autoimmune diseases.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page